Exosomes as nanocarriers for immunotherapy of cancer and inflammatory diseases

174Citations
Citations of this article
306Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Cell secreted exosomes (30-100. nm vesicles) play a major role in intercellular communication due to their ability to transfer proteins and nucleic acids from one cell to another. Depending on the originating cell type and the cargo, exosomes can have immunosuppressive or immunostimulatory effects, which have potential application as immunotherapies for cancer and autoimmune diseases. Cellular components shed from tumor cells or antigen presenting cells (APCs), such as dendritic cells, macrophages and B cells, have been shown to be efficiently packaged in exosomes. In this review, we focus on the application of exosomes as nanocarriers and immunological agents for cancer and autoimmune immunotherapy. APC-derived exosomes demonstrate effective therapeutic efficacy for the treatment of cancer and experimental autoimmune diseases such as rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. In addition to their intrinsic immunomodulating activity, exosomes have many advantages over conventional nanocarriers for drug and gene delivery.

Cite

CITATION STYLE

APA

Tran, T. H., Mattheolabakis, G., Aldawsari, H., & Amiji, M. (2015, September 1). Exosomes as nanocarriers for immunotherapy of cancer and inflammatory diseases. Clinical Immunology. Academic Press Inc. https://doi.org/10.1016/j.clim.2015.03.021

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free